About PeproMene bio inc.
PeproMene Bio, Inc is a clinical-stage biotech company in Irvine, California. We are committed to developing novel therapies to treat cancers and immune disorders. Our BAFF-R CAR-T therapy program is based on a novel antibody targeting the B-cell Activating Factor Receptor (BAFF-R) discovered by Dr. Larry Kwak’s team at MD Anderson Cancer Center, Houston, Texas, and City of Hope National Medical Center, Duarte, California.
BAFF (B cell activating factor), a soluble cytokine expressed by B cells is known for its proliferation and differentiation. In particular, BAFF-R (B cell activating factor receptor) is an excellent potential target for B-cell cancers not only because of its specificity on the BAFF, but also for its expression level by lymphoproliferative as well as leukemia-proliferative disorders.
PeproMene Bio, Inc. Announces Complete Remission of the Cohort 1 First Patient Treated for Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) in the Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope
Scientific publication update: ASH meeting abstract 2023 (Promising Safety and Anti-Lymphoma Efficacy of Autologous Pmb-CT01 (BAFFRCAR T Cell) Therapy in a First-in-Human Phase 1 Study)
PeproMene Bio, Inc. Announced Completion of the First Dose Cohort and Opening of the Second Dose Cohort in Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells)
PeproMene Bio, Inc. Announced Complete Response of The First Patient Treated in Its B-cell Non-Hodgkin Lymphoma (B-NHL) Phase 1 Clinical Trial of PMB-CT01 (BAFFR-CAR T Cells) at City of Hope
PeproMene’s platform and products targeting BAFF-R which is an innovative tumor antigen for treating a broad range of B cell malignancies and autoimmune diseases. BAFF-R targeting immune therapies have great potential to overcome the tumor relapse caused by antigen loss brings hope to those patients with such unmet medical needs. We value investors who share the same passion and welcome you to contact us for further information.